Eli Lilly said it plans to submit the pill to the Food and Drug Administration for approval as a weight loss medication this ...

Shandong Boan Biotechnology Company., Limited. Class H ( ($HK:6955) ) has shared an update. Shandong Boan Biotechnology Co., Ltd. has received ...

Eli Lilly and Company (NYSE:LLY) is one of the most profitable growth stocks to buy according to billionaires. On August 1, ...

Eli Lilly is poised for a major boost as new data shows its diabetes drug Mounjaro offers heart health benefits, potentially ...

Eli Lilly, a renowned drug manufacturer, stated that its GLP-1 pill, orforglipron, assisted individuals in reducing 12.4% of their weight following 72 weeks in a late-stage study.The company ...

A trial of Eli Lilly’s diabetes drug Mounjaro did not meet expectations for outperforming Trulicity in preventing heart ...

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.

At least 26 patients have filed lawsuits in Marion County against Eli Lilly and Co. over its marketing of GLP-1 drugs ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...

Topline results from the SURPASS-CVOT trial reveal that once-weekly tirzepatide (Mounjaro) has a cardiovascular risk profile ...